Insider Buying: Surrozen (NASDAQ:SRZN) Director Purchases $300,339.00 in Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey bought 15,100 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was bought at an average cost of $19.89 per share, with a total value of $300,339.00. Following the transaction, the director owned 989,893 shares in the company, valued at $19,688,971.77. This trade represents a 1.55% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Tim Kutzkey also recently made the following trade(s):

• On Friday, December 5th, Tim Kutzkey purchased 30,884 shares of Surrozen stock. The shares were purchased at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey purchased 5,266 shares of Surrozen stock. The stock was purchased at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The stock was purchased at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Down 3.0%

NASDAQ SRZN opened at $18.49 on Friday. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $24.94. The firm has a market capitalization of $158.46 million, a P/E ratio of -0.83 and a beta of 0.58. The company has a 50-day moving average price of $17.97 and a 200-day moving average price of $13.57.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million during the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. As a group, equities research analysts anticipate that Surrozen, Inc. will post -8.49 EPS for the current year.

Wall Street Analyst Weigh In

SRZN has been the topic of a number of recent analyst reports. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.00.

Institutional Investors Weigh In On Surrozen

A number of institutional investors have recently added to or reduced their stakes in SRZN. Citadel Advisors LLC raised its position in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares during the last quarter. Woodline Partners LP purchased a new position in Surrozen during the third quarter valued at $621,000. Armistice Capital LLC bought a new stake in Surrozen in the 2nd quarter valued at $536,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Surrozen in the 3rd quarter valued at $889,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.